151 related articles for article (PubMed ID: 21669266)
1. Paclitaxel conjugation with the analog of the gonadotropin-releasing hormone as a targeting moiety.
Pribylova M; Dvorakova M; Hanusova V; Nemethova I; Skalova L; Vanek T
Int J Pharm; 2011 Aug; 415(1-2):175-80. PubMed ID: 21669266
[TBL] [Abstract][Full Text] [Related]
2. Gonadotropin-releasing hormone receptor-targeted paclitaxel-degarelix conjugate: synthesis and in vitro evaluation.
Wang C; Ma Y; Feng S; Liu K; Zhou N
J Pept Sci; 2015 Jul; 21(7):569-76. PubMed ID: 25851250
[TBL] [Abstract][Full Text] [Related]
3. Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor--positive human cancer cell lines.
Pályi I; Vincze B; Kálnay A; Turi G; Mezõ I; Teplán I; Seprõdi J; Pató J; Móra M
Cancer Detect Prev; 1996; 20(2):146-52. PubMed ID: 8706040
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, characterization and in vitro cytotoxicity studies of a macromolecular conjugate of paclitaxel bearing oxytocin as targeting moiety.
Cavallaro G; Maniscalco L; Campisi M; Schillaci D; Giammona G
Eur J Pharm Biopharm; 2007 May; 66(2):182-92. PubMed ID: 17182230
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, in vitro stability, and antiproliferative effect of d-cysteine modified GnRH-doxorubicin conjugates.
Li S; Zhao H; Chang X; Wang J; Zhao E; Yin Z; Mao X; Deng S; Hao T; Wang H; Yang Y
J Pept Sci; 2019 Jan; 25(1):e3135. PubMed ID: 30467919
[TBL] [Abstract][Full Text] [Related]
6. Effect of gonadotropin-releasing hormone agonist on ES-2 ovarian cancer cells.
Tsui KH; Lee WL; Seow KM; Yang LW; Wang SY; Wang PH; Chang CL; Yen MS; Cheng JT; Chen CP
Taiwan J Obstet Gynecol; 2014 Mar; 53(1):35-42. PubMed ID: 24767644
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and active oxygen generation by new emodin derivatives and their gonadotropin-releasing hormone conjugates.
Lev-Goldman V; Mester B; Ben-Aroya N; Koch Y; Weiner L; Fridkin M
Bioconjug Chem; 2006; 17(4):1008-16. PubMed ID: 16848409
[TBL] [Abstract][Full Text] [Related]
8. Novel polymeric prodrug with multivalent components for cancer therapy.
Khandare JJ; Chandna P; Wang Y; Pozharov VP; Minko T
J Pharmacol Exp Ther; 2006 Jun; 317(3):929-37. PubMed ID: 16469865
[TBL] [Abstract][Full Text] [Related]
9. Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency.
Schottelius M; Berger S; Poethko T; Schwaiger M; Wester HJ
Bioconjug Chem; 2008 Jun; 19(6):1256-68. PubMed ID: 18510351
[TBL] [Abstract][Full Text] [Related]
10. Enhanced cellular uptake and in vitro antitumor activity of short-chain fatty acid acylated daunorubicin-GnRH-III bioconjugates.
Hegedüs R; Manea M; Orbán E; Szabó I; Kiss E; Sipos E; Halmos G; Mező G
Eur J Med Chem; 2012 Oct; 56():155-65. PubMed ID: 22967796
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.
Safavy A; Bonner JA; Waksal HW; Buchsbaum DJ; Gillespie GY; Khazaeli MB; Arani R; Chen DT; Carpenter M; Raisch KP
Bioconjug Chem; 2003; 14(2):302-10. PubMed ID: 12643740
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro biological evaluation of daunorubicin containing GnRH-I and GnRH-II conjugates developed for tumor targeting.
Szabó I; Bősze S; Orbán E; Sipos É; Halmos G; Kovács M; Mező G
J Pept Sci; 2015 May; 21(5):426-35. PubMed ID: 25908176
[TBL] [Abstract][Full Text] [Related]
13. Gonadotropin-releasing hormone type II induces apoptosis of human endometrial cancer cells by activating GADD45alpha.
Wu HM; Cheng JC; Wang HS; Huang HY; MacCalman CD; Leung PC
Cancer Res; 2009 May; 69(10):4202-8. PubMed ID: 19366794
[TBL] [Abstract][Full Text] [Related]
14. Growth inhibition of tumor cells in vitro by using monoclonal antibodies against gonadotropin-releasing hormone receptor.
Lee G; Ge B
Cancer Immunol Immunother; 2010 Jul; 59(7):1011-9. PubMed ID: 20182875
[TBL] [Abstract][Full Text] [Related]
15. Peptides and antitumor activity. Development and investigation of some peptides with antitumor activity.
Teplán I
Acta Biol Hung; 2000; 51(1):1-29. PubMed ID: 10866357
[TBL] [Abstract][Full Text] [Related]
16. Heparin-paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity.
Wang Y; Xin D; Liu K; Zhu M; Xiang J
Bioconjug Chem; 2009 Dec; 20(12):2214-21. PubMed ID: 19950889
[TBL] [Abstract][Full Text] [Related]
17. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.
Föst C; Duwe F; Hellriegel M; Schweyer S; Emons G; Gründker C
Oncol Rep; 2011 May; 25(5):1481-7. PubMed ID: 21331448
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, characterization and systematic comparison of FITC-labelled GnRH-I, -II and -III analogues on various tumour cells.
Murányi J; Gyulavári P; Varga A; Bökönyi G; Tanai H; Vántus T; Pap D; Ludányi K; Mező G; Kéri G
J Pept Sci; 2016 Aug; 22(8):552-60. PubMed ID: 27443981
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a stable gonadotropin-releasing hormone analog in mice for the treatment of endocrine disorders and prostate cancer.
Katsila T; Balafas E; Liapakis G; Limonta P; Montagnani Marelli M; Gkountelias K; Tselios T; Kostomitsopoulos N; Matsoukas J; Tamvakopoulos C
J Pharmacol Exp Ther; 2011 Mar; 336(3):613-23. PubMed ID: 21106905
[TBL] [Abstract][Full Text] [Related]
20. Novel gonadotropin-releasing hormone antagonists with substitutions at position 5.
Samant MP; Hong DJ; Croston G; Rivier C; Rivier J
Biopolymers; 2005; 80(2-3):386-91. PubMed ID: 15614806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
